SIERRA ONCOLOGY, INC.
SUPPLEMENT TO THE PROXY STATEMENT
FOR THE 2020 ANNUAL MEETING OF
TO BE HELD ON JUNE 9, 2020
This proxy statement supplement, dated May 26, 2020,
supplements the definitive proxy statement (“Proxy
Statement”) of Sierra Oncology, Inc. (the “Company”)
relating to the Company’s Annual Meeting of Stockholders to be held
on June 9, 2020 at 10:00 a.m. (Pacific Time) via live webcast
by visiting www.virtualshareholdermeeting.com/SRRA2020. This
supplement should be read in conjunction with the Proxy Statement.
Capitalized terms used in this supplement and not otherwise defined
herein have the meanings given to them in the Proxy Statement.
Departure of Dr. Nick Glover as President, Chief Executive
Officer and Director
On May 22, 2020, Dr. Nick Glover, the President and Chief
Executive Officer of the Company and member of the Company’s Board
of Directors (the “Board”), resigned from such roles
effective as of the same date.
In connection with Dr. Glover’s departure, the Company expects
to enter into a separation agreement with Dr. Glover
consistent with the terms of his employment agreement which will be
described in a future Current Report on Form 8-K to be filed by the Company.
Appointment of Dr. Stephen Dilly as President, Chief
Executive Officer and Director
On May 21, 2020, the Board appointed Dr. Stephen G.
Dilly, M.B.B.S., Ph.D., to serve as the Company’s President and
Chief Executive Officer and as a Class III director on the
Board effective June 1, 2020 (the “Dilly Start
Dr. Dilly, 60, served as Chief Executive Officer of Aimmune
Therapeutics, a biopharmaceutical company, from April 2014 to June
2018 and as a member of Aimmune’s board of directors from April
2013 to June 2018. Dr. Dilly was Chief Executive Officer of
PhotoThera, Inc., a medical device company, from January 2012 to
December 2012. Since 2010, Dr. Dilly has served as an
independent director of Sangamo Therapeutics, Inc., where he also
currently serves as chair of the clinical review committee.
Dr. Dilly also currently serves on the boards of directors of
Codexis, Inc. and of several private biotechnology companies. From
2006 to 2011, Dr. Dilly served as President and Chief
Executive Officer and a member of the board of directors of APT
Pharmaceuticals, Inc. From 2007 to 2009, he was a member of the
board of directors of Avigen, Inc., which merged with MediciNova,
Inc. in December 2009. From 2003 to 2006, he served as Chief
Medical Officer and Senior Vice President of Development of Chiron
BioPharma, which was later acquired by Novartis International AG.
From 1998 to 2003, Dr. Dilly held various management positions
at Genentech, Inc., including Vice President of Development
Sciences from 2002 to 2003 and Vice President of Medical Affairs
from 1998 to 2001. From 1988 to 1998, Dr. Dilly held various
management positions in drug development with SmithKline Beecham,
PLC, a healthcare company in the U.K. Dr. Dilly received a
M.B.B.S. from the University of London in the U.K. and a Ph.D. in
cardiac physiology from University of London.